Outcome of treatment in patients with small cell lung cancer in poor performance status

Bahij, Rana; Jeppesen, Stefan Starup; Olsen, Karen Ege; Halekoh, Ulrich; Holmskov, Karin; Hansen, Olfred

doi:10.1080/0284186x.2019.1637934

Cited by 12 publications

(12 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar evidence has been shown by other studies (19,25,26) .It was found also that advanced stages of cancer (stage III&IV) had a significant risk factor for death (HR=6.661) than early lung cancer stages (stage I&II) in both univariate and multivariate analysis (p=0.0001) and this is consistent with previous study (19) . As regard performance status, our study revealed that performance status equal to or more than 2 was also a significant risk factor of mortality(HR=3.514 and p=0.001) than performance status less than 2.Other publications on performance status and survival confirmed the significant longer survival in patient with lower performance status (19,22,35) .…”

Section: Discussionsupporting

confidence: 64%

Risk factors analysis for mortality among a cohort of lung cancer patients

Mohamed

Said

kamal

et al. 2022

Minia Journal of Medical Research

View full text Add to dashboard Cite

Background: Over the last few decades, the worldwide burden of cancer has been increased. More than half of the 18.1 million people diagnosed with cancer in 2018 died. Lung cancer diagnoses and deaths are on the rise. So that it is very important to investigate the factors that influence lung cancer mortality. The aim is to assess the characteristics of lung cancer patients and the factors influencing mortality due to lung cancer. Methods: A cross-sectional observational study was performed on 58 lung cancer patients (48 with Non-Small Cell Lung cancer(NSCLC) and 10 with Small Cell Lung Cancer(SCLC) with a mean age 58.9 yrs. Fortynine of them were males, one third were current smokers and 56% of them had advanced stage of lung cancer (stage III and IV). Survival was calculated from the date of enrollment in the study to the date of the last follow-up visit (3 years) or death. Results: Seventy-five of the studied patients died with an average survival duration of 19 months for NSCLC patients in comparison to 12 months for SCLC patients. Patients > 60 yrs., those with SCLC, current smokers and those with performance status ≥ 2 had a low survival time. Univariate regression analysis identified that advanced stage of cancer had a 6-fold increase in mortality (p=0.0001). Conclusion: Age more than 60, performance status ≥ 2 and stage III and IV were found as significant independent factors linked with raised mortality rate.

show abstract

Section: Discussionsupporting

confidence: 64%

Risk factors analysis for mortality among a cohort of lung cancer patients

Mohamed

Said

kamal

et al. 2022

Minia Journal of Medical Research

View full text Add to dashboard Cite

show abstract

“…Carboplatin (AUC5, Calvert formula) was administrated intravenously on day one, and etoposide (240 mg/m 2 ) was given orally daily from day one to three. 7 A previous study with weekly etoposide and platinum doublet in patients of SCLC unfit for standard regimen found the weekly regimen as a valid option with no excess toxicity. The clinical benefit rate was achieved by 57% of the patients in their study.…”

Section: Discussionmentioning

confidence: 99%

“…However, the median OS was poor (2.7 months) for the patients ( n = 6) with a PS of 4. Carboplatin (AUC5, Calvert formula) was administrated intravenously on day one, and etoposide (240 mg/m 2 ) was given orally daily from day one to three 7 . A previous study with weekly etoposide and platinum doublet in patients of SCLC unfit for standard regimen found the weekly regimen as a valid option with no excess toxicity.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy in geriatric patients with poor performance status small cell lung cancer: Series from a tertiary care center

Sundriyal

Kumar

et al. 2022

Aging Medicine

View full text Add to dashboard Cite

show abstract

“…The chance of being offered treatment decreased with PS. A recent study of ES-SCLC patients aged ≥70 years reported a 7.8-and 0.6-month median OS among participants who received chemotherapy and no treatment, respectively (15); those who received A B (14 months), chemoradiotherapy led to a substantial increase in OS (19 months). These findings are largely consistent with those of previous retrospective and randomized research on TRT, which have suggested the survival benefit of TRT concurrent with chemotherapy for systematic ES-SCLC.…”

Section: Discussionmentioning

confidence: 99%

A nomogram to predict the overall survival of patients with symptomatic extensive-stage small cell lung cancer treated with thoracic radiotherapy

Zheng

Liu

Gao

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: Small cell lung cancer (SCLC) makes up 13% of lung malignancies. Only one-third of SCLC patients received their diagnosis at the limited stage. Treatment for symptomatic extensive-stage (ES) SCLC with persistent intrathoracic disease is still controversial. The present research aimed to analyze the impact of palliative thoracic radiotherapy (TRT) as a treatment for this patient group and build a prognostic nomogram.Methods: In this retrospective, multi-center study, we analyzed 120 patients with ES-SCLC and a World Health Organization performance status of 1-2 who were diagnosed between March 2014 and September 2019. A nomogram was formulated to predict the patients' 1-and 2-year overall survival (OS). Results:The study cohort had a median age of 62 years, and males accounted for 85% of enrollees. A significant extension was observed in the median OS in the TRT group compared to the no TRT group (P<0.001). When the patients were stratified by TRT dose, no significant differences in OS were noted (P=0.530). However, higher levels of inflammatory markers prior to TRT were associated with a shorter OS (neutrophil-to-lymphocyte ratio, P=0.002; platelet/lymphocyte ratio, P=0.023). The nomogram's Harrell's concordance (C)-statistic reached 0.70, and the calibration curve analysis revealed goodness of fit. Conclusions:The neutrophil-to-lymphocyte ratio is an independent factor predicting survival in ES-SCLC patients treated with palliative TRT. Our nomogram, which incorporates immunological markers, has higher accuracy than existing models for the prediction of individuals' chances of survival, and it could be a significant tool for clinicians in the development of tailored therapeutic strategies.

show abstract

Outcome of treatment in patients with small cell lung cancer in poor performance status

Cited by 12 publications

References 31 publications

Risk factors analysis for mortality among a cohort of lung cancer patients

Risk factors analysis for mortality among a cohort of lung cancer patients

Chemotherapy in geriatric patients with poor performance status small cell lung cancer: Series from a tertiary care center

A nomogram to predict the overall survival of patients with symptomatic extensive-stage small cell lung cancer treated with thoracic radiotherapy

Contact Info

Product

Resources

About